Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg.
Publication/Presentation Date
1-1-2022
Volume
134
Issue
sup1
First Page
1
Last Page
4
ISSN
1941-9260
Published In/Presented At
Kyrillos, J. V., O'Neil, P. M., & Wharton, S. (2022). Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg. Postgraduate medicine, 134(sup1), 1–4. https://doi.org/10.1080/00325481.2022.2149005
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
36691310
Department(s)
Administration and Leadership
Document Type
Article